Waltz Quoted on ROI from Anti-Fraud Efforts Under President Trump
March 20, 2017
Bloomberg BNA
Partner Judy Waltz was quoted in a Bloomberg BNA article, “Trump Budget Would Boost Spending to Fight Medicare, Medicaid Fraud,” covering the ideal return on investment from anti-fraud efforts, and the integrity of the Trump administration’s anti-fraud program as a whole.
Waltz explains that the support for program integrity “is because the [Health Care Fraud and Abuse Control] program has been able to demonstrate a good return on investment, both in actual dollars and in the nonquantifiable deterrent side as well.”
She continues to say that, however, “with the administration’s statements about reducing regulatory burdens, there may be less emphasis on fraud, waste and abuse allegations that reflect regulatory noncompliance [in the future].”
Waltz explains that the support for program integrity “is because the [Health Care Fraud and Abuse Control] program has been able to demonstrate a good return on investment, both in actual dollars and in the nonquantifiable deterrent side as well.”
She continues to say that, however, “with the administration’s statements about reducing regulatory burdens, there may be less emphasis on fraud, waste and abuse allegations that reflect regulatory noncompliance [in the future].”
People
Related News
August 13, 2025
In the News
Leigh Riley on Elevating Partner Development with Foley's PEAK Program – 'We can't stop learning'
Foley & Lardner LLP partner Leigh Riley appeared on the Big Law Life podcast to share how Foley is redefining professional development to meet the needs of the firm's partners and the demands of modern legal practice.
August 8, 2025
In the News
Gregory Husisian and David Simon Uncover the High Stakes of Tariff Evasion
Foley & Lardner LLP partners Gregory Husisian and David Simon are featured for their insights on how the U.S. government is cracking down on tariff evaders in the Newsweek article, "America Is Making Billions From Catching 'Tariff Cheaters.'"
August 7, 2025
In the News
Kyle Faget Weighs in on Trump Pharma Tariffs
Foley & Lardner LLP partner Kyle Faget assessed the Trump administration's implementation of import tariffs on the pharmaceutical industry in the Pharma Life Sciences article, "Trump's pharma import tariffs threaten drug pricing, generics."